Allogene Therapeutics Inc

NASDAQ:ALLO   12:20:14 PM EDT
10.58
+0.08 (+0.76%)
Products

Allogene Therapeutics Announces Removal Of FDA Clinical Hold Across All Allocar T Clinical Trials

Published: 01/10/2022 13:54 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All Allocar T™ Clinical Trials.
Allogene Therapeutics Inc - Investigation Confirmed Chromosomal Abnormality in a Single Patient Was Not Observed in Any Allocar T Product.
Allogene Therapeutics Inc - Clinical Trials Across Allocar T Platform to Resume.
Allogene - Pivotal Phase 2 Trial of Allo-501a in Relapsed/refractory Large B Cell Lymphoma Expected to Commence in Mid-year 2022 Pending FDA Discussions.
Allogene Therapeutics Inc - Abnormality Was Not Detected in Any Manufactured Allocar T Product Or in Any Other Patient Treated With Same Allo-501a Lot.